Review Article

You have free access to this content

Chronic myelogenous leukemia: Laboratory diagnosis and monitoring

  1. Y. Lynn Wang,
  2. Adam Bagg,
  3. Warren Pear,
  4. Peter C. Nowell,
  5. Jay L. Hess*

Article first published online: 25 JUL 2001

DOI: 10.1002/gcc.1171

Issue

Genes, Chromosomes and Cancer

Genes, Chromosomes and Cancer

Volume 32, Issue 2, pages 97–111, October 2001

Additional Information

How to Cite

Wang, Y. L., Bagg, A., Pear, W., Nowell, P. C. and Hess, J. L. (2001), Chronic myelogenous leukemia: Laboratory diagnosis and monitoring. Genes Chromosom. Cancer, 32: 97–111. doi: 10.1002/gcc.1171

Author Information

  1. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

*Department of Pathology and Laboratory Medicine, University of Pennsylvania, 413b Stellar-Chance Building, 422 Curie Blvd., Philadelphia, PA 19104-6100

Publication History

  1. Issue published online: 29 AUG 2001
  2. Article first published online: 25 JUL 2001
  3. Manuscript Accepted: 8 APR 2001
  4. Manuscript Received: 23 DEC 2000

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (177K)

REFERENCES

  • Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, Fioretos T, Mitelman F, Hoglund M. 1997. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 20: 299–304.
    Direct Link:
  • Aurich J, Duchayne E, Huguet-Rigal F, Bauduer F, Navarro M, Perel Y, Pris J, Caballin MR, Dastugue N. 1998. Clinical, morphological, cytogenetic and molecular aspects of a series of Ph-negative chronic myeloid leukemias. Hematol Cell Ther 40: 149–158.
  • Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen AC, Landegren U. 2000. Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem 46: 913–920.
  • Bentz M, Cabot G, Moos M, Speicher MR, Ganser A, Lichter P, Dohner H. 1994. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 83: 1922–1928.
  • Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. 1995. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86: 3118–3122.
  • Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. 1998. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92: 3362–3367.
  • Branford S, Hughes TP, Rudzki Z. 1999. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107: 587–599.
    Direct Link:
  • Brizard F, Chomel JC, Veinstein A, Rivet J, Giraud C, Kitzis A, Guilhot F, Brizard A. 1998. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy? Leukemia 12: 1076–1080.
  • Buno I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW. 1998. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 92: 2315–2.
  • Calabrese G, Stuppia L, Franchi PG, Peila R, Morizio E, Liberati AM, Spadano A, DiLorenzo R, Donti E, Antonucci A, et al. 1994. Complex translocations of the Ph chromosome and Ph negative CML arise from similar mechanisms, as evidenced by FISH analysis. Cancer Genet Cytogenet 78: 153–159.
  • Chomel JG, Brizard F, Veinstein A, Rivet J, Sadoun A, Kitzis A, Guilhot F, Brizard A. 2000. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 95: 404–408.
  • Clift RA, Storb R. 1996. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 17(Suppl 3): S1–53.
  • Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM. 1995. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 75: 464–470.
    Direct Link:
  • Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. 1993. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82: 1929–1936.
  • Cuneo A, Bigoni R, Emmanuel B, Smit E, Rigolin GM, Roberti MG, Bardi A, Piva N, Scapoli G, Castoldi G, Van Den Berghe H, Hagemeijer A. 1998. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 12: 1718–1723.
  • Cunningham I, Gee T, Dowling M, Chaganti R, Bailey R, Hopfan S, Bowden L, Turnbull A, Knapper W, Clarkson B. 1979. Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 53: 375–395.
  • Delage R, Soiffer RJ, Dear K, Ritz J. 1991. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 78: 2759–2767.
  • Dewald GW, Schad CR, Christensen ER, Tiede AL, Zinsmeister AR, Spurbeck JL, Thibodeau SN, Jalal SM. 1993. The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL. Cancer Genet Cytogenet 71: 7–14.
  • Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, Spurbeck JL, Silver RT. 1998. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 91: 3357–3365.
  • Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M. 1992. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. Leukemia 6: 754–760.
  • Drobyski WR, Endean DJ, Klein JP, Hessner MJ. 1997. Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia. Br J Haematol 98: 458–466.
    Direct Link:
  • Druker BJ, Lydon NB. 2000. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3–7.
  • Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J, Sawyer CL. 1999. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Blood 94(Suppl.): 368a.
  • Duba HC, Peter S, Hilbe W, Fluckinger T, Fridrik M, Erdel M, Thaler J, Utermann G. 1999. Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha. Int J Oncol 14: 145–150.
  • Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B. 1999. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 13: 1383–1389.
  • Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW. 2000. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol 79: 424–431.
  • Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A. 1999. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13: 1825–1832.
  • Estop AM, Sherer C, Cieply K, Groft D, Burcoglu A, Jhanwar S, Thomas J. 1997. A Ph-negative chronic myeloid leukemia patient with a non-classical BCR-ABL rearrangement characterized by fluorescence in situ hybridization. Cancer Genet Cytogenet 96: 174–176.
  • Faderl S, Talpaz M, Estrov Z, Kantarjian HM. 1999a. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131: 207–219.
  • Faderl S, Talpaz M, Kantarjian HM, Estrov Z. 1999b. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 93: 2755–2759.
  • Gaiger A, Lion T, Kalhs P, Mitterbauer G, Henn T, Haas O, Fodinger M, Kier P, Forstinger C, Quehenberger P, et al. 1993. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT). Leukemia 7: 1766–1772.
  • Garcia-Isidoro M, Tabernero MD, Garcia JL, Najera ML, Hernandez JM, Wiegant J, Raap A, San Miguel J, Orfao A. 1997. Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: comparison with conventional cytogenetics and implications for minimal residual disease detection. Hum Pathol 28: 154–159.
  • Ghaffari S, Daley GQ, Lodish HF. 1999. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia 13: 1200–1206.
  • Glassman AB. 1998. Cytogenetics, in situ hybridization and molecular approaches in the diagnosis of cancer. Ann Clin Lab Sci 28: 324–330.
  • Grand FH, Chase A, Iqbal S, Nguyen DX, Lewis JL, Marley SB, Davidson RJ, Goldman JM, Gordon MY. 1998. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia. Genes Chromosomes Cancer 23: 109–1015.
    Direct Link:
  • Gratwohl A, Hermans J. 1996. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 17(Suppl 3): S7–9.
  • Gribble SM, Sinclair PB, Grace C, Green AR, Nacheva EP. 1999. Comparative analysis of G-banding, chromosome painting, locus-specific fluorescence in situ hybridization, and comparative genomic hybridization in chronic myeloid leukemia blast crisis. Cancer Genet Cytogenet 111: 7–17.
  • Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. 1984. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93–99.
  • Harrison CJ, Gibbons B, Yang F, Butler T, Cheung KL, Kearney L, Dirscherl L, Bray-Ward P, Gregson M, Ferguson-Smith M. 2000. Multiplex fluorescence in situ hybridization and cross species color banding of a case of chronic myeloid leukemia in blastic crisis with a complex Philadelphia translocation. Cancer Genet Cytogenet 116: 105–1010.
  • Haskovec C, Ponzetto C, Polak J, Maritano D, Zemanova Z, Serra A, Michalova K, Klamova H, Cermak J, Saglio G. 1998. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. Br J Haematol 103: 1104–1108.
    Direct Link:
  • Heim S, Mitelman F. 1995. Cancer genetics, 2nd ed. New York: Wiley-Liss.
  • Hermans A, Heisterkamp N, von Linden M, van Baal S, Meijer D, van der Plas D, Wiedemann LM, Groffen J, Bootsma D, Grosveld G. 1987. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 51: 33–40.
  • Hess JL. 1998. Detection of chromosomal translocations in leukemia. Is there a best way? Am J Clin Pathol 109: 3–5.
  • Hester JP, Waddell CC, Coltman CA Jr, Morrison FS, Stephens RL, Balcerzak SP, Baker LH, Chen TT. 1984. Response of chronic myelogenous leukemia patients to COAP-splenectomy. A Southwest Oncology Group study. Cancer 54: 1977–1982.
    Direct Link:
  • Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. 1996a. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87: 1549–1555.
  • Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NC. 1996b. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88: 2236–2240.
  • Hochhaus A, Feldman E, Goldman JM, Miller C, Ben-Am M, Capdeville R, Druker B. 2000a. A phase II study to determine the safety and anti-leukemic effects of STI 571 in patients with Philadelphia chromosome positive chronic meyloid leukemia in myeloid blast crisis. Blood 96: 503a.
  • Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. 2000b. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95: 62–66.
  • Hughes TP, Morgan GJ, Martiat P, Goldman JM. 1991. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 77: 874–878.
  • Iwata S, Mizutani S, Nakazawa S, Yata J. 1994. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia 8: 1696–1702.
  • Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. 1987. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83: 445–454.
  • Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. 1988. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61: 1441–1446.
    Direct Link:
  • Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. 1993. Chronic myelogenous leukemia: a concise update. Blood 82: 691–703.
  • Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. 1995. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122: 254–261.
  • Kantarjian HM, Sawyers C, Hochhaus A, Guilhot F, Shiffer C, Resta D, Capdeville R, Druker B. 2000. Phase II study of STI 571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome positive chronic meyloid leukemia. Blood 96: 470a.
  • Kirk JA, Radich J, Edmands S, Lee A, VanDevanter DR, Reems JA, Bryant EM. 1996. Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemia. Am J Hematol 52: 129–134.
    Direct Link:
  • Kobzev Y, Domracheva E, Zakharova A, Khoroshko N, Turkina A, Dewald G. 1998. Fluorescence in situ hybridization studies of interphase nuclei for assessing response to therapy in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 106: 128–134.
  • Kojima K, Yasukawa M, Ishimaru F, Dansako H, Matsuo Y, Kimura Y, Nawa Y, Hara M, Harada M. 1999. Additional translocation (8;21)(q22;q22) in a patient with Philadelphia-positive chronic myelogenous leukaemia in the blastic phase. Br J Haematol 106: 720–722.
    Direct Link:
  • Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462–2465.
  • Kreuzer KA, Lass U, Bohn A, Landt O, Schmidt CA. 1999. LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 59: 3171–3174.
  • Kurzrock R, Kantarjian HM, Shtalrid M, Gutterman JU, Talpaz M. 1990. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood 75: 445–452.
  • Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. 1998. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 16: 1526–1531.
  • Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA. 1992. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 79: 1920–1923.
  • Lichty BD, Keating A, Callum J, Yee K, Croxford R, Corpus G, Nwachukwu B, Kim P, Guo J, Kamel-Reid S. 1998. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol 103: 711–715.
    Direct Link:
  • Lin F, van Rhee F, Goldman JM, Cross NC. 1996. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87: 4473–4478.
  • Lion T. 1994. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. The European Investigators on Chronic Myeloid Leukemia Group. Bone Marrow Transplant 14: 505–509.
  • Lion T, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H. 1992. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 6: 495–499.
  • Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. 1993. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 341: 275–276.
  • Lion T, Gaiger A, Henn T, Horth E, Haas OA, Geissler K, Gadner H. 1995. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 9: 1353–1360.
  • Lugo TG, Pendergast AM, Muller AJ, Witte ON. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079–1082.
  • Mackinnon S, Barnett L, Heller G. 1996. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 17: 643–647.
  • Mahon FX, Faberes C, Pueyo S, Cony-Makhoul P, Salmi R, Boiron JM, Marit G, Bilhou-Nabera C, Carrere A, Montastruc M, Pigneux A, Bernard P, Reiffers J. 1998. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood 92: 4059–4065.
  • Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM. 1996. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14: 196–203.
  • Malinge MC, Mahon FX, Delfau MH, Daheron L, Kitzis A, Guilhot F, Tanzer J, Grandchamp B. 1992. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br J Haematol 82: 701–707.
    Direct Link:
  • Melo JV. 1996. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88: 2375–2384.
  • Melo JV. 1997. BCR-ABL gene variants. Baillieres Clin Haematol 10: 203–222.
  • Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A, De Witte T. 1998. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 102: 768–774.
    Direct Link:
  • Moravcova J, Lukasova M, Stary J, Haskovec C. 1998. Simple competitive two-step RT-PCR assay to monitor minimal residual disease in CML patients after bone marrow transplantation. Leukemia 12: 1303–1312.
  • Muhlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G, Duba HC. 1998. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer 21: 90–100.
    Direct Link:
  • Nacheva E, Holloway T, Brown K, Bloxham D, Green AR. 1994. Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol 87: 409–412.
    Direct Link:
  • Nanjangud G, Kadam PR, Saikia T, Bhisey AN, Kumar A, Gopal R, Chopra H, Nair CN, Advani SH. 1994. Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis. Leukemia Res 18: 385–392.
  • Nowell P, Hungerford D. 1960. A minute chromosome in chronic granulocytic leukemia. Science 132: 1497.
  • Paldi-Haris P, Barta A, Lengyel L, Batai A, Masszi T, Remenyi P, Denes R, Paloczi K, Kelemen E, Foldi J. 1994. Molecular background of a new case of chronic myelogenous leukemia with bcr-abl chimera mRNA lacking the A2 exon. Leukemia 8: 1791.
  • Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B. 1996. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88: 2410–2414.
  • Paschka P, Schoch C, Lahaye T, Weisser A, Kuhn C, La Rosee P, Kreil S, Berger U, Haferlach A, Gschaidmerer H, Hehlmann R, Hochhaus A. 2000. Monitoring the response of CML patients treated with STI 571 by molecular cytogenetics and quantitative RT-PCR. Blood 96: 734a.
  • Polak J, Koza V, Cetkovsky P, Haskovec C. 2000. An accelerated-phase CML patient with e19a2 junction of BCR/ABL gene — the first case of transplanted CML with micro bcr [Letter]. Bone Marrow Transplant 25: 1109–1110.
  • Porter DL, Antin JH. 1999. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 50: 369–386.
  • Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, et al. 1995. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 85: 2632–2638.
  • Reiter A, Marley SB, Hochhaus A, Sohal J, Raanani P, Hehlmann R, Gordon MY, Goldman JM, Cross NC. 1998. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha. Br J Haematol 102: 1271–1278.
    Direct Link:
  • Roth MS, Antin JH, Ash R, Terry VH, Gotlieb M, Silver SM, Ginsburg D. 1992. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 79: 276–282.
  • Roumier C, Daudignon A, Soenen V, Dupriez B, Wetterwald M, Lai JL, Cosson A, Fenaux P, Preudhomme C. 1999. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders? Haematologica 84: 1075–1080.
  • Rowley JD. 1973. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290–293.
  • Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, Rege-Cambrin G, Mazza U, Gavosto F. 1990. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 76: 1819–1824.
  • Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio A, de Micheli D, Parziale A, Fornaci MN, Martinelli G, Salvatore F. 1996. Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 87: 1075–80.
  • Sawyers CL. 1999. Chronic myeloid leukemia. N Engl J Med 340: 1330–1340.
  • Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. 2000. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289: 1938–1942.
  • Selleri L, Emilia G, Luppi M, Temperani P, Zucchini P, Tagliafico E, Artusi T, Sarti M, Donelli A, Castoldi GL, et al. 1990. Chronic myelogenous leukemia with typical clinical and morphological features can be Philadelphia chromosome negative and “bcr negative.” Hematol Pathol 4: 67–77.
  • Seong DC, Song MY, Henske EP, Zimmerman SO, Champlin RE, Deisseroth AB, Siciliano MJ. 1994. Analysis of interphase cells for the Philadelphia translocation using painting probe made by inter-Alu-polymerase chain reaction from a radiation hybrid. Blood 83: 2268–2273.
  • Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR, Deisseroth AB, Champlin RE, Siciliano MJ. 1995. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 86: 2343–2349.
  • Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S. 1999. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94: 1517–1536.
  • Sinclair PB, Green AR, Grace C, Nacheva EP. 1997. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 90: 1395–1402.
  • Su XY, Wong N, Cao Q, Yu LZ, Niu C, Wickham N, Johnson PJ, Chen Z, Chen SJ. 1999. Chromosomal aberrations during progression of chronic myeloid leukemia identified by cytogenetic and molecular cytogenetic tools: implication of 1q12-21. Cancer Genet Cytogenet 108: 6–12.
  • Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. 1991. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 114: 532–538.
  • Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. 1994. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 94: 1383–1389.
  • Talpaz M, Silver RT, Druker B, Paquette R, Goldman JM, Reese SF, Capdeville R. 2000. A phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase. Blood 96: 469a.
  • Thijsen S, Schuurhuis G, van Oostveen J, Ossenkoppele G. 1999. Chronic myeloid leukemia from basics to bedside. Leukemia 13: 1646–1674.
  • Thompson JD, Brodsky I, Yunis JJ. 1992. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 79: 1629–1635.
  • Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Suryanarayan K, Homge M, Redner A, Gray J, Pinkel D. 1990. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 250: 559–562.
  • Tyagi S, Kramer FR. 1996. Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 14: 303–308.
  • van der Plas DC, Soekarman D, van Gent AM, Grosveld G, Hagemeijer A. 1991. bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient. Leukemia 5: 457–461.
  • van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. 1996. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 87: 5213–5217.
  • van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, de Witte T, Kolb HJ, Niederwiser D, Jacobsen N, Gahrton G, Bandini G, Carreras E, Bacigalupo A, Michallet M, Ruutu T, Reiffers J, Goldman JM, Apperley J, Gratwohl A. 1997. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20: 553–560.
  • Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, Pherwani R, Rios MB, Stass SA, Kantarjian HM. 1995. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 85: 2705–2710.
  • Warmuth M, Danhauser-Riedl S, Hallek M. 1999. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol 78: 49–64.
  • Werner M, Ewig M, Nasarek A, Wilkens L, von Wasielewski R, Tchinda J, Nolte M. 1997. Value of fluorescence in situ hybridization for detecting the bcr/abl gene fusion in interphase cells of routine bone marrow specimens. Diagn Mol Pathol 6: 282–287.
  • Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. 1997. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22: 130–131, 134-138.
  • Yanagi M, Shinjo K, Takeshita A, Tobita T, Yano K, Kobayashi M, Terasaki H, Naoe T, Ohnishi K, Ohno R. 1999. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia 13: 542–552.
  • Yehuda O, Abeliovich D, Ben-Neriah S, Sverdlin I, Cohen R, Varadi G, Orr R, Ashkenazi YJ, Heyd J, Lugassy G, Ben Yehuda D. 1999. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. Cancer Genet Cytogenet 114: 100–107.
  • Yoffe G, Blick M, Kantarjian H, Spitzer G, Gutterman J, Talpaz M. 1987. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 69: 961–963.
View Full Article (HTML) Get PDF (177K)